Prescient Therapeutics Opens SPP to Raise $7m
Key points
- Prescient Therapeutics opens Share Purchase Plan (SPP) to raise up to $7 million.
- Eligible shareholders can acquire new shares at $0.065 per share.
- Funds will support PTX-100 development and other business activities.
Full summary
Prescient Therapeutics (ASX: PTX) has announced the opening of a Share Purchase Plan (SPP) to raise up to $7 million. Eligible shareholders can purchase new shares at $0.065 each, an 18.8% discount to the 10-day VWAP. The SPP follows a year of strong operational delivery, including progress in the Phase 2a clinical trial. The funds will support the advancement of PTX-100 beyond the Dose Optimisation Committee meeting targeted for the second half of 2026, aiming for regulatory approval and broader patient access. Shareholders registered as of August 24, 2026, can apply for up to $30,000 of new shares. The SPP will close on September 8, 2026. A shareholder briefing is scheduled for August 28, 2026.
Guidance
Prescient Therapeutics plans to raise up to $7 million through the SPP.
Outlook
The company aims to advance PTX-100 beyond the Dose Optimisation Committee review and progress into the next stage of development.
Summary generated by a large language model. Please interpret with care.